Lesson
Build the Genetic Vocabulary
Pharmacogenomics begins with precise language. A variant is not automatically functional, a genotype is not a phenotype, and an inherited result is not the same kind of evidence as a tumor biomarker.
- DNA and genes
- Variants and alleles
- Genotype and phenotype
- Germline and somatic
Identify what differs and whether the assay can resolve it.
Place variants on each chromosome before assigning function.
Translate inherited structure into gene-specific activity.
Move from sequence to function
DNA is organized into genes on chromosomes. A sequence variant can alter expression, protein function, or neither. A single nucleotide variant changes one position, while insertions, deletions, copy-number changes, and other structural variants can change larger regions or gene dosage.
Name the inherited result
An allele is a version of a gene. A haplotype is a set of variants inherited together on one chromosome. A diplotype is the pair of haplotypes carried across the two homologous chromosomes. The laboratory genotype must be translated through known function before a clinical phenotype is assigned.
Separate genotype from phenotype
Genotype describes detected inherited variation. Phenotype describes the resulting functional category or observed trait. The same phenotype label can mean different functional thresholds across genes, and drugs can differ in how strongly they depend on the affected pathway.
Separate germline from somatic testing
Germline pharmacogenomics estimates inherited differences that may apply across many tissues and future prescriptions. Somatic tumor testing characterizes an evolving cancer clone and can identify a treatment target or resistance marker. These results answer different questions and should not be merged into one generic genetic test.
Quick check
Checking for saved practice…
Lesson
Connect Gene Expression to Drug Response
Sequence variation can change how much RNA is produced, how RNA is processed, or how a protein is built and functions. Pharmacogenomics therefore reaches beyond coding substitutions alone.
- Central dogma
- Regulatory variation
- RNA splicing
- Protein function
- Epigenetics
Locate coding, splice, regulatory, and structural variation.
Trace abundance, splicing, and transcript stability.
Test the functional consequence before inferring response.
Follow information from DNA to protein
Transcription produces a complementary RNA copy of a gene. RNA processing adds protective ends and joins retained exons after introns are removed. Translation then uses messenger RNA codons to assemble a polypeptide that folds and may undergo further modification.
Locate the variant before predicting effect
A coding variant can alter an amino acid, introduce a stop signal, shift the reading frame, or leave the amino acid unchanged. Promoter, enhancer, splice-site, untranslated-region, and copy-number variants can alter expression or processing without changing the encoded amino acid sequence.
Distinguish association from mechanism
A statistically associated marker may be causal, may track with the causal variant through linkage disequilibrium, or may be a false-positive result. Functional studies can test effects on expression, protein activity, transport, or metabolism, but laboratory effects still require clinical validation.
Add regulatory context
DNA sequence is stable, while gene expression can vary by tissue, development, inflammation, environment, and epigenetic state. This helps explain why the same inherited variant may not determine the entire observed medication response.
Quick check
Checking for saved practice…
Lesson
Choose a Method That Can Answer the Question
PCR, sequencing, genotyping arrays, and broader omics platforms observe different layers of biology. A method is useful only when its analytical coverage matches the clinical question.
- PCR
- Sequencing
- Genotyping arrays
- Proteomics
- Metabolomics
- Analytical validity
Interrogate known regions or predefined alleles efficiently.
Expand coverage while retaining platform-specific blind spots.
Observe dynamic downstream products of biological pathways.
Amplify a defined target
Polymerase chain reaction uses primers, nucleotides, a heat-stable polymerase, and temperature cycling to amplify a selected DNA region. Reverse-transcription PCR first converts RNA to complementary DNA, so it can examine expressed transcripts rather than genomic DNA alone.
Compare targeted and broad approaches
Targeted genotyping efficiently detects predefined alleles but cannot exclude variants it does not interrogate. Sequencing can survey a gene, panel, exome, or genome, yet read depth, phasing, pseudogenes, repeats, and structural variation can still limit interpretation.
Use arrays and multi-omics deliberately
Genotyping arrays test many predefined markers and can support genome-wide association work. Proteomics measures proteins and their states, while metabolomics measures small-molecule products of pathways. These downstream layers can capture functional context but are more dynamic than inherited DNA.
Separate analytical from clinical validity
Analytical validity asks whether the assay accurately detects its target. Clinical validity asks whether the result predicts the phenotype of interest. Clinical utility asks whether using the result improves a meaningful decision or outcome. Strength in one domain does not guarantee the others.
Quick check
Checking for saved practice…
Lesson
Translate Alleles Into Function
A report becomes clinically useful only after allele definitions, copy number, diplotype, function, and phenotype are translated correctly. Medication exposure can then reshape the observed phenotype through phenoconversion.
- Star alleles
- Allele function
- Activity score
- Copy number
- Phenoconversion
Define the functional alleles carried by the patient.
Apply the current gene-specific translation model.
Add inhibitors, inducers, disease, and organ function.
Read star alleles as haplotypes
A star allele names a defined haplotype, not a single universal variant. Two star alleles form a diplotype. Different laboratories may test different variant panels, so a reported absence of common variants does not prove that every function-altering allele was excluded.
Use gene-specific function
Alleles can be assigned no, decreased, normal, or increased function when evidence supports that classification. Some genes use activity scores to combine allele function before assigning ultrarapid, rapid, normal, intermediate, or poor metabolizer status. Not every gene uses every category.
Resolve structural variation
Copy-number gains, deletions, hybrids, and tandem arrangements can alter function and are especially important for genes such as CYP2D6. An assay that cannot resolve structural variation may return an incomplete or ambiguous phenotype.
Recognize phenoconversion
A genotype-predicted normal metabolizer can function like a lower-activity phenotype when a strong inhibitor is present. Induction, inflammation, organ dysfunction, and adherence can also change observed exposure. Genotype remains stable, but the medication phenotype is contextual.
Quick check
Checking for saved practice…
Lesson
Choose the Right Evidence Layer
FDA labeling, the FDA association table, CPIC, other guideline groups, and companion diagnostics serve different roles. Safe implementation begins by asking which source answers the current question.
- FDA labeling
- FDA association table
- CPIC
- Companion diagnostic
- Assay quality
Read requirements, associations, and explicit limitations.
Translate an available result in the correct indication.
Match biomarker, assay, specimen, and therapeutic label.
Read the FDA association table carefully
The FDA table organizes gene-drug associations by evidence and management relevance. Inclusion does not necessarily mean FDA recommends testing before prescribing unless the test is a companion diagnostic. The table is not comprehensive and does not replace approved labeling.
Use CPIC for an available result
CPIC primarily answers how an available genotype should be used to optimize therapy. It does not generally decide whether a clinician should order the test. Other organizations, payer policies, local programs, and product labels may address testing strategy differently.
Identify companion diagnostics
A companion diagnostic provides information essential for the safe and effective use of a corresponding therapeutic product. The therapeutic label and diagnostic instructions define the required specimen, method, biomarker, and treatment context.
Build a clinical workflow
Define the medication question, select a validated assay, verify specimen and coverage, translate the result, incorporate interacting drugs and organ function, apply the current source, discuss implications, document the interpretation, and monitor the actual clinical outcome.
Quick check
Checking for saved practice…
Lesson
Interrogate Pharmacogenomic Evidence
Genomic studies can produce impressive associations that fail to replicate or never become clinically useful. Critical appraisal links study design, phenotype, statistics, biology, and prescribing consequence.
- Candidate gene
- GWAS
- Phenotype definition
- Multiple testing
- Replication
- Clinical utility
Match the search strategy to the hypothesis and multiplicity burden.
Confirm comparable populations, outcomes, and direction of effect.
Ask whether testing changes care in a way that benefits patients.
Distinguish study strategies
A candidate-gene study evaluates prespecified variants based on a biological hypothesis. A genome-wide association study scans large numbers of markers without limiting the search to one pathway. The broad search can reveal unexpected biology but creates a major multiple-testing burden.
Audit cases, controls, and phenotype
Misclassified exposure or outcome can dilute or fabricate an association. Cases and controls should come from comparable populations, population structure should be addressed, and the phenotype should reflect the clinical effect that the proposed recommendation claims to predict.
Demand replication and functional coherence
A credible association should reproduce in an independent population with a comparable phenotype and direction of effect. Functional studies can strengthen plausibility, but neither statistical significance nor laboratory mechanism alone proves that genotype-guided prescribing improves outcomes.
Move from association to implementation
Effect size, absolute risk, allele frequency, assay performance, treatment alternatives, feasibility, equity, and patient values determine clinical utility. A guideline should disclose its evidence methods, recommendation strength, version, conflicts, and intended population.
Quick check
Checking for saved practice…
Lesson
Counsel Before and After Testing
A pharmacogenomic result can influence today’s prescription, future treatment, relatives, privacy, and patient expectations. Counseling should make the result understandable without overstating certainty.
- Pretest counseling
- Actionability
- Limitations
- Patient values
- Post-test counseling
- Documentation
Discuss benefit, process, alternatives, limitations, and data use.
Explain the result, medication change, uncertainty, and monitoring.
Confirm understanding and preserve a versioned result for reuse.
Prepare the pretest conversation
Explain the medication question, expected benefit, specimen and process, alternatives, cost and access, possible limitations, privacy and data handling, future relevance, and whether disease-risk or familial information could emerge. Invite the patient’s goals and concerns before testing.
Interpret before presenting
Confirm actionability, exact alleles and assay coverage, genotype-to-phenotype translation, current guideline or label, interacting drugs, organ function, and the strength of the recommendation. A nonactionable or uncertain result should not be dressed up as a definitive medication command.
Deliver a usable post-test plan
State the result in plain language, describe any immediate drug or dose change, explain what remains uncertain, identify monitoring and follow-up, and discuss future prescriptions that may be affected. Provide a durable patient-facing summary and referrals when broader genetic counseling is appropriate.
Document for safe reuse
Store the original laboratory result, assay, genotype, translated phenotype, source version, limitations, medication implication, counseling provided, and responsible follow-up. Reinterpretation may be necessary when allele definitions or guidance changes.
Quick check
Checking for saved practice…
Lesson
Prevent Selected HLA-Associated Reactions
HLA alleles can identify markedly increased risk for selected immune-mediated reactions. A positive result can change drug selection, while a negative result never replaces symptom recognition and urgent response.
- HLA-B*57:01
- HLA-B*58:01
- HLA-B*15:02
- HLA-A*31:01
- SCAR
Avoid if positive and never rechallenge after suspected hypersensitivity.
Avoid if positive because severe-cutaneous-reaction risk is high.
Apply the drug and allele-specific risk pathway.
Protect abacavir use
Test for HLA-B*57:01 before initial abacavir use and before reinitiation when prior status is unknown. Do not use abacavir in a positive patient. If hypersensitivity is suspected, stop the drug and never rechallenge, even if the result is negative.
Reduce allopurinol SCAR risk
HLA-B*58:01 strongly increases risk of allopurinol severe cutaneous adverse reactions. CPIC recommends avoiding allopurinol when positive. Who should receive preemptive testing can vary by guideline and population, so ancestry can inform test probability but cannot substitute for the result.
Resolve carbamazepine risk
HLA-B*15:02 is associated most strongly with carbamazepine and oxcarbazepine SJS or TEN in selected ancestral populations. HLA-A*31:01 is associated with a broader carbamazepine hypersensitivity spectrum. A negative result for one allele does not exclude other genetic or clinical risk.
Preserve vigilance
Genetic tests have defined targets, sensitivity, and coverage. Counsel patients to stop and seek urgent evaluation for concerning rash, mucosal involvement, fever, facial edema, or systemic symptoms according to the drug and clinical plan.
Quick check
Checking for saved practice…
Lesson
Interpret CYP2D6-Activated Opioids
Codeine and tramadol require CYP2D6-mediated formation of more active metabolites. Too little activation can reduce benefit, while excessive activation can increase toxicity.
- Codeine
- Tramadol
- CYP2D6
- Ultrarapid metabolizer
- Poor metabolizer
- Phenoconversion
Codeine or tramadol may provide inadequate opioid effect.
Check inhibitors because phenotype can still convert.
Avoid activation-dependent opioids when toxicity risk rises.
Follow activation
CYP2D6 converts codeine to morphine and contributes to tramadol formation of O-desmethyltramadol. Poor metabolizers may obtain inadequate opioid effect. Ultrarapid metabolizers may form active metabolite quickly and face greater toxicity.
Use phenotype-guided selection
CPIC recommends avoiding codeine in CYP2D6 poor metabolizers because of likely inefficacy and in ultrarapid metabolizers because of serious toxicity risk. Tramadol has a similar directional concern. Choose an alternative not dependent on CYP2D6 activation when appropriate.
Add regulatory safety constraints
FDA restrictions for children and warnings during breastfeeding are separate from genotype. A favorable genotype does not make codeine appropriate in a contraindicated age group or remove the risk of infant opioid exposure through breast milk.
Account for inhibitors
Strong CYP2D6 inhibition can reduce active metabolite formation and produce functional phenoconversion. Medication reconciliation is therefore part of every genotype interpretation.
Quick check
Checking for saved practice…
Lesson
Match CYP2C19 to Antiplatelet Context
Clopidogrel is a prodrug whose active-metabolite formation depends partly on CYP2C19. Reduced function matters most when the clinical setting has strong evidence for genotype-guided selection.
- Clopidogrel
- CYP2C19
- ACS
- PCI
- Neurovascular
- Alternative P2Y12 inhibitor
Loss-of-function alleles reduce active metabolite formation.
Use an alternative in reduced-function phenotypes when appropriate.
Apply the indication-specific evidence and contraindications.
Link phenotype to activation
CYP2C19 intermediate and poor metabolizers form less clopidogrel active metabolite, have less platelet inhibition, and can have higher ischemic-event risk. Increased-function alleles can contribute to rapid or ultrarapid phenotypes but do not justify ignoring bleeding risk.
Prioritize ACS and PCI evidence
For acute coronary syndrome or percutaneous coronary intervention, CPIC recommends avoiding standard-dose clopidogrel in intermediate and poor metabolizers when an appropriate alternative P2Y12 inhibitor is available and not contraindicated.
Respect indication-specific evidence
Recommendations for neurovascular disease differ in strength and alternatives may carry indication-specific limitations. Apply the correct CPIC table, product labeling, bleeding risk, contraindications, and treatment duration for the actual clinical scenario.
Avoid false precision
Genotype affects one activation pathway. Adherence, absorption, interacting drugs, diabetes, obesity, smoking, platelet biology, and procedural factors can also influence outcome.
Quick check
Checking for saved practice…
Lesson
Integrate HLA and CYP2C9 in Antiseizure Therapy
Antiseizure pharmacogenomics can affect both immune safety and dose-related exposure. HLA and CYP2C9 results answer different questions and should be interpreted together with nonlinear kinetics and measured concentrations.
- Phenytoin
- Fosphenytoin
- CYP2C9
- HLA-B*15:02
- Carbamazepine
- Oxcarbazepine
Reduced function can require a lower phenytoin maintenance start.
A positive result can change antiseizure-drug selection.
Nonlinear kinetics and binding still govern adjustment.
Translate CYP2C9 for phenytoin
Reduced CYP2C9 function lowers phenytoin clearance. CPIC uses genotype-predicted phenotype to guide a reduced maintenance starting strategy after any clinically indicated loading dose. Subsequent adjustment still depends on response and appropriately timed total or unbound concentrations.
Add HLA-B*15:02
HLA-B*15:02 increases risk of phenytoin-associated SJS or TEN in relevant populations. A positive result generally supports avoiding phenytoin or fosphenytoin when an alternative is available, independent of the CYP2C9 dose recommendation.
Distinguish aromatic agents
Carbamazepine and oxcarbazepine share HLA-B*15:02 concerns, while HLA-A*31:01 adds a broader carbamazepine hypersensitivity signal. Cross-reactivity and prior severe reactions require drug-specific specialist judgment.
Monitor nonlinear exposure
Phenytoin metabolism is saturable. Genotype can inform the starting strategy, but small dose changes can cause disproportionate concentration changes. Binding changes can make an unbound concentration more informative than a total value.
Quick check
Checking for saved practice…
Lesson
Prevent Severe Antimetabolite Toxicity
TPMT and NUDT15 influence thiopurine tolerance, while DPYD influences fluoropyrimidine catabolism. Partial and complete deficiency require different strategies and continued laboratory surveillance.
- TPMT
- NUDT15
- Thiopurines
- DPYD
- Fluoropyrimidines
- Myelosuppression
Combine both pathways before choosing a starting dose.
Distinguish intermediate from poor metabolism.
Genotype-guided dosing never replaces surveillance.
Assess both thiopurine genes
TPMT and NUDT15 both affect thiopurine tolerance through different mechanisms. Reduced function can cause excessive active nucleotide exposure and profound myelosuppression. Testing only TPMT can miss clinically important NUDT15 risk.
Individualize the starting strategy
The 2025 CPIC update distinguishes single-gene intermediate status, compound TPMT and NUDT15 intermediate status, and any poor-metabolizer combination. It also separates malignant from nonmalignant use and asks whether the intended starting dose is already below the standard threshold. A compound intermediate phenotype can need a greater initial reduction than a single intermediate phenotype, while poor-metabolizer combinations can require a drastically reduced intermittent regimen for malignancy or a nonthiopurine alternative for nonmalignant disease.
Translate DPYD carefully
Reduced DPD activity raises fluorouracil and capecitabine exposure. CPIC uses DPYD activity scores to distinguish normal, intermediate, and poor metabolizers. Intermediate metabolizers generally need a reduced starting strategy with titration, while complete deficiency can require avoidance.
Keep monitoring active
Genotype does not predict every toxicity. CBC, liver tests, renal function, infection symptoms, gastrointestinal toxicity, mucositis, hand-foot syndrome, and treatment response remain clinically important according to the regimen.
Quick check
Checking for saved practice…
Lesson
Use Multigene Results Without Losing the Patient
Some decisions integrate several genes, interacting drugs, laboratory values, and clinical factors. Warfarin and statin examples show why an algorithm or phenotype supports a starting strategy rather than replacing follow-up.
- CYP2C9
- VKORC1
- CYP4F2
- Warfarin
- SLCO1B1
- Statins
- UGT1A1
Combine genotype with clinical variables for initiation.
Match transporter function to drug, dose, and treatment goal.
Let observed benefit and harm guide ongoing therapy.
Build a warfarin estimate
CYP2C9 affects S-warfarin clearance, VKORC1 influences target sensitivity, and CYP4F2 can contribute to dose requirement. A validated algorithm can combine genotype with age, body size, interacting drugs, ancestry-relevant variants, and indication when results are available.
Continue INR management
A genotype-informed initial estimate does not replace INR measurement, dose titration, adherence review, dietary consistency, interaction management, or bleeding and thrombotic assessment. The patient's response becomes the most direct dosing evidence after therapy begins.
Reduce statin muscle risk
SLCO1B1 reduced function can increase exposure to selected statins and the risk of muscle symptoms, with the effect varying by drug and dose. CPIC can guide statin and dose selection when a result is available without implying that every patient requires testing.
Recognize other actionable pathways
UGT1A1 can alter irinotecan toxicity risk, while CYP2C19 can inform selected proton-pump inhibitor and antidepressant decisions. Each gene-drug pair has its own evidence, phenotype translation, and clinical boundary.
Quick check
Checking for saved practice…
Lesson
Read Tumor Biomarkers as Treatment Gates
Tumor biomarkers can identify a therapeutic target, a resistance mechanism, or eligibility for a companion diagnostic-directed treatment. They are dynamic, specimen-dependent, and distinct from inherited metabolizer phenotypes.
- HER2
- RAS
- BRAF
- EGFR
- Companion diagnostic
- Tumor heterogeneity
Identify a treatment-sensitive tumor state.
Detect biology that can block expected benefit.
Confirm the authorized specimen, assay, indication, and therapy.
Identify the biomarker's clinical role
HER2 overexpression or amplification can identify tumors likely to benefit from selected HER2-directed therapies. RAS mutations can predict lack of benefit from selected EGFR-directed therapy in colorectal cancer. A ctDNA molecular-residual-disease result can now serve as an FDA-authorized companion-diagnostic treatment-selection gate in a defined muscle-invasive bladder-cancer setting. Target presence, resistance, and residual-disease detection are different biomarker roles.
Use the authorized context
FDA-authorized companion diagnostics link a specific test or group-labeled test with defined therapeutic products and indications. A positive result from an unvalidated specimen or assay is not automatically interchangeable with the approved testing pathway.
Account for tumor evolution
Tumor heterogeneity, treatment pressure, clonal selection, low tumor fraction, and sampling site can alter what is detected. A negative result can reflect biology or assay limitations, and a prior result may not represent current disease.
Protect the germline boundary
A tumor test can incidentally suggest an inherited variant, but confirmation requires an appropriate germline specimen and counseling pathway. Tumor-only results should not be presented as proof of inherited family risk.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 196 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- FDA. Table of Pharmacogenetic Associations.
- FDA. Pharmacogenomic Biomarkers in Drug Labeling.
- FDA. List of FDA-Authorized Companion Diagnostic Devices.
- CPIC. Guidelines and implementation resources.
- CPIC. CYP2C19 genotype and clopidogrel therapy, 2022 update.
- CPIC. CYP2D6, OPRM1, and COMT genotypes and opioid therapy.
- CPIC. TPMT and NUDT15 genotypes and thiopurine dosing, 2025 update.
- CPIC. DPYD genotype and fluoropyrimidine therapy.
- CPIC. CYP2C9 and HLA genotypes and phenytoin dosing.
- CPIC. HLA genotype and carbamazepine or oxcarbazepine use.
- CPIC. HLA-B genotype and allopurinol dosing.